Oncotelic Therapeutics, Inc. Noncontrolling Interest, Increase from Subsidiary Equity Issuance
Oncotelic Therapeutics, Inc. (OTLC) reported Noncontrolling Interest, Increase from Subsidiary Equity Issuance of $620.05 thousand for the 12-month period ending 2021-12-31, per its 10-K/A filed 2023-04-20.
Discontinued › Shareholders' Equity
us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance · last filed 2023-04-20
- Oncotelic Therapeutics, Inc. noncontrolling interest, increase from subsidiary equity issuance for the quarter ending 2021-03-31 was $620.05K.
- Oncotelic Therapeutics, Inc. noncontrolling interest, increase from subsidiary equity issuance for fiscal 2021 was $620.05K, a 47.37% decline from fiscal 2020.
- Oncotelic Therapeutics, Inc. noncontrolling interest, increase from subsidiary equity issuance for fiscal 2020 was $1.18M.
| Period end | Noncontrolling Interest, Increase from Subsidiary Equity Issuance 3 month | Noncontrolling Interest, Increase from Subsidiary Equity Issuance 12 month |
|---|---|---|
| 2021-12-31 | $620.05K 10-K/A · filed 2023-04-20 | |
| 2021-03-31 | $620.05K 10-Q · filed 2022-11-18 | |
| 2020-12-31 | $1.18M 10-K · filed 2022-04-15 |